Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
Posted by amanda punzalan under Press (No Respond)
Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease MZE001 Was Well Tolerated and Reduced Glycogen Accumulation in Blood Cells in Healthy Volunteers Phase 1 Results Support Advancement into…